InsiderTrades

Form 4 for RARE Ultragenyx Pharmaceutical Inc.

Accepted 2025-03-03 00:00:00 ET · period of report 2025-02-27 · accession 0000950170-25-030639 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2025-03-03 2025-02-27 RARE Parschauer Karah Herdman EVP, CLO S - Sale $42.88 -2,990 55.0K -5% -$128.2K
D 2025-03-03 2025-03-01 RARE Parschauer Karah Herdman EVP, CLO A - Grant $0.00 +14.5K 69.7K +26% $0
D 2025-03-03 2025-03-01 RARE Parschauer Karah Herdman EVP, CLO A - Grant $0.00 +26.1K 26.1K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-02-27 S D 2,230 $42.93 55,751 D — —
2 Common Common Stock 2025-02-27 S D 760 $42.75 54,991 D — —
3 Common Common Stock 2025-03-01 A A 14,494 $0.00 69,690 D — — (F1) Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date (F3) Includes 205 shares acquired on October 31, 2024 under the Company's Amended and Restated Employee Stock Purchase Plan (F2) Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
4 Derivative Stock Option (Right to Buy) 2025-03-01 A A 26,074 $0.00 26,074 D $42.92 · — to 2035-03-01 26,074 Common Stock (F4) On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.